Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus PREMASOL 6 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus PREMASOL 6 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs PREMASOL 6% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
Intravenous amino acid solution providing essential and non-essential amino acids for protein synthesis, nitrogen balance, and maintenance of lean body mass. Amino acids are actively transported into cells and incorporated into proteins; also serves as a caloric source.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
Intravenous infusion: 1 to 1.5 g/kg/day (amino acids) as part of total parenteral nutrition; typically 500 mL to 1000 mL per day, infused over 12-24 hours.
None Documented
None Documented
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Amino acids have rapid plasma clearance; elimination half-life varies from minutes to hours depending on individual amino acid; clinically, infused amino acids are cleared within 2-4 hours after infusion cessation.
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Renal elimination of amino acids and metabolites; complete metabolism with nitrogen excretion as urea in urine; minimal biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution